ICIs, particularly PD-1/PD-L1 antibodies such as nivolumab, have been approved by the United States Food and Drug Administration for the treatment of GI malignancies, including GC, HCC, and CRC (Table 1). The gene discussed is CD274; the disease is gastric cancer.